
The Uterine Carcinosarcoma Market was valued at USD 25.72 billion in 2025 and is projected to reach USD 42.56 billion by 2033, growing at a CAGR of 6.50% from 2026 to 2033. The market is witnessing steady growth driven by increasing incidence of rare and aggressive uterine cancers, improved diagnostic accuracy through advanced imaging and molecular testing, and rising awareness regarding early oncological screening and personalized treatment approaches.
3 Views
